Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities
Net loss	$ (76,257)	$ (53,298)
Adjustments to reconcile net loss to net cash used for operating activities:
Share-based compensation expense	14,429	10,804
Third party share-based compensation expense	747	167
Depreciation expense	899	510
Loss on disposal of equipment	0	75
Changes in operating assets and liabilities:
Restricted cash	(711)	37
Prepaid expenses and other current assets	(267)	(660)
Other assets	219	(149)
Accounts payable	(413)	(508)
Accrued clinical and other expenses	(234)	2,693
Accrued payroll and related expenses	1,151	231
Net cash used for operating activities	(60,437)	(40,098)
Investing activities
Purchase of property and equipment	(4,288)	(1,419)
Net cash used for investing activities	(4,288)	(1,419)
Financing activities
Net proceeds from the issuance of common stock	117,480	0
Proceeds from the exercise of stock options for common stock	2,359	85
Net cash provided by financing activities	119,839	85
Net increase (decrease) in cash and cash equivalents	55,114	(41,432)
Cash and cash equivalents at beginning of period	65,726	126,467
Cash and cash equivalents at end of period	$ 120,840	$ 85,035